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Surveillance for Antimicrobial
Resistance in Croatia
Arjana Tambic Andraševic,* Tera Tambic,† Smilja Kalenic,‡ and Vera Jankovic,§ and the 
Working Group of the Croatian Committee for Antibiotic Resistance Surveillance1
We describe the activities of the Croatian Committee for Antibiotic Resistance Surveillance and report surveil-
lance results for 1999. Twenty-two Croatian microbiology laboratories participated in the study. Resistance
rates for the organisms isolated in different centers varied widely, but certain trends were apparent. Penicillin
resistance in pneumococci (38%), methicillin resistance in Staphylococcus aureus (22%), the production of
extended spectrum beta-lactamases by  Klebsiella pneumoniae  (21%), and imipenem resistance in
Pseudomonas aeruginosa (11%) represent major resistance problems, especially in large hospitals. A com-
prehensive system of antimicrobial resistance surveillance, combined with training and external quality con-
trol programs, has identified high rates of resistance in key pathogens in some regions of Croatia. The
program has heightened awareness of the problems of antimicrobial resistance and contributed to ongoing
improvements in laboratory practice.
ntimicrobial resistance is a well-recognized problem
worldwide (1). Resistant organisms are more likely in
intensive care settings (2), where a combination of debilitated
patients, invasive technology, and high antimicrobial use facili-
tates infections by multidrug-resistant staphylococci, entero-
bacteria resistant to third-generation cephalosporins, and
imipenem-resistant nonfermentative bacteria. However, resis-
tance is also a growing problem in community-acquired infec-
tions. Of particular concern are penicillin-resistant
pneumococci (3-5) and the extended-spectrum beta-lactamase-
producing enterobacteria (6). In addition, the World Health
Organization (WHO) and the International Union against
Tuberculosis and Lung Disease have shown that resistant
tuberculosis (TB) is a problem in many parts of the world (7).
Antimicrobial resistance often leads to therapeutic failure of
empirical therapy; therefore, knowledge of the local prevalence
of pathogens and their antimicrobial sensitivity patterns is
essential for clinicians in their routine work. Clinicians should
also be aware of the sensitivity patterns in both neighboring
and distant areas. 
In 1996, the Croatian Academy of Medical Sciences estab-
lished the Committee for Antibiotic Resistance Surveillance in
Croatia. The aims of the committee are to standardize methods
for antimicrobial sensitivity testing in laboratories throughout
the country, collect local data on antimicrobial resistance, and
share the information with clinicians and pharmaceutical com-
panies. The ultimate goal is a more appropriate use of antimi-
crobial agents in empirical therapy of infectious diseases. We
present results of the surveillance for 1999 and describe the
organization and activities of the committee. 
Methods
Administration and Activities
Seventeen microbiology laboratories, representing the
major geographic regions of the country, were initially asked to
join the committee. Membership is now open to all 32 labora-
tories in Croatia. By 1999, 22 laboratories had joined the com-
mittee (Figure 1). The committee also includes infectious
disease and clinical pharmacology specialists who are inter-
ested in antimicrobial resistance.
The committee meets twice a year to identify pathogens
and antimicrobial agents to be surveyed in the next study
period (June 1 to December 31). A smaller working group is
set up to organize surveillance and produce forms for data col-
lection. The forms are sent to the collaborating centers, then
returned to the working group for analysis. The committee also
organizes a focused study of one particular clinical problem
(e.g., a study on methicillin-resistant Staphylococcus aureus
[MRSA] and two studies of blood-culture isolates). Each year
the committee summarizes its results in reports sent to the col-
laborating centers and made available publicly.
 Educational Activities
The first Croatian Symposium on Antibiotic Resistance
was organized in 1993. After the Committee for Antibiotic
Resistance Surveillance was founded, it assumed responsibility
for organizing these symposia every 3 years. The committee
also organizes a biannual Workshop on Antibiotic Resistance
at the Croatian Congress of Infectious Diseases. Each year, in
collaboration with the local office of the Croatian Medical
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Association, the committee organizes a 1-day meeting on anti-
biotic resistance in different counties. In addition, the commit-
tee organizes an annual course on laboratory methods that is
mandatory and free of charge for the heads of the collaborating
laboratories.
Quality Control
The Department of Microbiology at the University Hospi-
tal for Infectious Diseases in Zagreb participates in the WHO
and Centers for Disease Control and Prevention External Qual-
ity Assurance program and acts as Croatian coordinator for
member laboratories. This is the only organized quality assur-
ance program in Croatia, and all committee members are
required to participate. The laboratories are also encouraged to
use the WHONET program for internal quality control.
 Surveillance and Laboratory Methods
The surveillance period was from June 1 to December 31,
1999. Organisms selected for surveillance included group A
streptococcus,  Streptococcus pneumoniae, Staphylococcus
aureus, Enterococcus spp., Escherichia coli, Klebsiella spp.,
Proteus  spp.,  Enterobacter  spp.,  Acinetobacter  spp.,
Pseudomonas aeruginosa, Salmonella spp., and Shigella spp.
Laboratories were asked to record all nonduplicate isolates of
these species during the surveillance period and their sensitivi-
ties to selected antimicrobial agents. The information was
recorded on paper forms and returned to the working group.
The isolates were collected from all body sites, and surveil-
lance of routine data did not include differentiation of coloni-
zation from infection. Data for  Mycobacterium tuberculosis
were adapted from the annual report of the Croatian Reference
Laboratory for Tuberculosis, which includes data from all lab-
oratories in the country that process specimens for TB. 
Identification of Bacteria
All organisms were assessed by colony morphology and
Gram stain. All the laboratories used the DNA-base and slide
coagulase tests for identification of S. aureus, bacitracin disk
for group A Streptococcus, and optochin disk for S. pneumo-
niae. Enterobacteria and P. aeruginosa were identified by dif-
ferent methods in different laboratories.
Antimicrobial Sensitivity Testing
All participating laboratories used the disk diffusion
method of the National Committee for Clinical Laboratory
Standards for antimicrobial sensitivity testing (8). Disks for the
selected antimicrobial agents were provided by the committee
to ensure that all isolates were tested for all agents requested. 
Results
The centers providing data included 22 hospital and public
health laboratories (Figure 1). Resistance rates for the organ-
isms isolated in different centers varied widely, but certain
trends were apparent.
Gram-Positive Bacteria (Figure 2)
Among group A Streptococcus isolates, the overall resis-
tance was 19% to erythromycin and 6% to clindamycin. S.
pneumoniae isolates included those from primarily sterile
sites, as well as from respiratory specimens and nasopharyn-
geal swabs. Resistance to penicillin and other antimicrobial
agents was common. Both penicillin and cotrimoxazole resis-
tance averaged 38%, macrolide resistance 23%, and tetracy-
cline resistance 21%. Chloramphenicol resistance was
relatively uncommon, averaging 7%. 
These figures, however, obscure a wide range of results
from different centers. Penicillin resistance ranged from 8% in
Osijek to 62% in Cakovec; erythromycin and azythromicin
resistance from 9% in Dubrovnik to 31% in one Zagreb center;
and cotrimoxazole resistance from 14% in Sisak to 70% in
Pula. 
Overall, 18% of Croatian isolates of S. aureus were resis-
tant to oxacillin (and therefore methicillin). Methicillin-resis-
tant strains were often multidrug resistant, averaging 65%
resistance to gentamicin, 49% to clindamycin, 57% to ciprof-
loxacin, and 50% to rifampicin. Resistance to fucidic acid
(5%), cotrimoxazole (7%), and mupirocin (7% when tested by
a 5-mg disk) was uncommon. Again, wide variation in resis-
tance rates was seen, with strikingly low rates of MRSA in the
Cakovec General Hospital. 
Overall, only 2% of Enterococcus spp. isolates were resis-
tant to ampicillin and 1% to nitrofurantoin. Resistance to gen-
tamicin was 12% (when tested by a 120-mg disk), and
vancomycin-resistant isolates occurred in only one Zagreb
hospital (with 4% resistance). 
Gram-Negative Bacteria (Figure 3)
Approximately half the E. coli isolates were resistant to
ampicillin, and 15% were resistant to beta-lactam/beta-lacta-
Figure 1. Croatian microbiology laboratories participating in surveillance
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mase inhibitor combinations. Approximately 24% of isolates
were resistant to cotrimoxazole, 13% to cefuroxime, 4% to
ceftazidime, 7% to gentamicin, 5% to ciprofloxacin, and none
to imipenem. In almost all centers, resistance to ampicillin was
>40% and to cotrimoxazole >20%. In one
Zagreb hospital, resistance to ceftazidime
reached 15%, but in most centers it was <4%. 
Klebsiella organisms showed a high degree
of multidrug resistance: 34% were resistant to
co-amoxiclav or ampicillin+sulbactam, 33% to
cefuroxime, and 21% to both ceftazidime and
gentamicin. These organisms also showed
moderate resistance (8% to 10%) to the other
clinically available aminoglycosides (netilmi-
cin and amikacin) but were generally sensitive
to ciprofloxacin (6% resistance). No imipenem
resistance was recorded. However, resistance
rates varied widely, with ceftazidime resistance
ranging from 2% to 39%, gentamicin resis-
tance from 2% to 44%, and ciprofloxacin resis-
tance from 1% to 17%. 
Croatian isolates of  P. aeruginosa  also
showed high rates of resistance and multidrug
resistance, again with variation among centers.
The overall rates of resistance (and ranges for
different centers) were piperacillin 22% (7% to
57%), ceftazidime 7% (2% to 20%), imipenem
11% (0% to 21%), gentamicin 44% (20% to
69%), and ciprofloxacin 33% (16%
to 60%). 
Salmonellas generally showed
good sensitivity to all antimicrobial
agents except ampicillin (19%
resistant) and chloramphenicol (6%
resistant). Shigellas were highly
resistant to ampicillin (87%), tetra-
cycline (79%), and cotrimoxazole
(89%). Resistance to other antimi-
crobial agents was <10%.
There was no imipenem resis-
tance in enterobacteriaceae, but in
Acinetobacter spp. it was 1% (0%
to 8%). A high percentage (53% to
88%) of  Acinetobacter isolates
were resistant to many antimicro-
bial agents, except to the combina-
tion ampicillin + sulbactam (18%
resistance), amikacin (25% resis-
tance), and netilmicin (26% resis-
tance).  Proteus  spp. isolates
generally showed good sensitivity
to antimicrobial agents except to
ampicillin (49% resistance) and
cotrimoxazole (28% resistance).
Enterobacter spp. were often multi-
drug resistant, with stable resistance to ceftazidime of 31%.
In 1999, 5,664 isolates of M. tuberculosis were recovered
in 17 laboratories; 316 (5.9%) of them were resistant to one of
the first-line antituberculosis drugs (streptomycin, izoniazid,
Figure 2. Resistance rates (%) to selected antimicrobial agents in gram-positive bacteria in Croatia (June 1
to December 31, 1999). The number of resistant organisms / number of organisms tested is given in brack-
ets. Note: macrolide resistance = resistance to erythromycin and azithromycin; penicillin resistance in
pneumococci = nonsusceptibility to penicillin; gentamicin resistance in enterococci = high-level resistance.
Figure 3. Resistance rates (%) to selected antimicrobial agents in gram-negative bacteria in
Croatia (June 1 – December 31, 1999). The number of resistant organisms/number of organ-
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rifampin, pyrazinamid, or ethambutol). However, among
newly diagnosed cases of TB, only 3% of isolates were resis-
tant to one of the first-line drugs and 0.6% of isolates were
multidrug resistant, i.e., resistant to rifampicin plus isoniazid.
Discussion
Croatian national data suggest that resistance is occurring
in both community and hospital-acquired infections. S. pneu-
moniae is a major community-acquired pathogen. Resistance
to penicillin of 38% has prompted an ongoing centralized
study, which could also provide an estimate of the proportion
of highly resistant strains.
MRSA is common, especially in large hospitals and on
trauma wards. The incidence of MRSA increased rapidly dur-
ing the early 1990s, frequently causing chronic osteomyelitis
after war injuries. Observations in a trauma hospital in Zagreb
suggest that MRSA spread throughout Croatia is facilitated by
lack of screening and isolation facilities and poor interhospital
communication (9,10). Some areas, such as the Medimurje
region (city of Cakovec), are still almost unaffected by MRSA,
and screening of all surgery and intensive-care unit patients
transferred there from other centers is highly recommended. 
Croatia does not seem to have a nationwide problem with
vancomycin-resistant enterococci. Such isolates appear to be
limited to the Clinical Hospital Center Zagreb, the largest hos-
pital in Zagreb (11). Cotrimoxazole is still widely used in
Croatia as the first-line antimicrobial agent for urinary tract
infections. In many centers, resistance of  E. coli and other
enterobacteriaceae to this agent exceeds 20%, which indicates
the need for alternative therapy for uncomplicated urinary tract
infections. Production of extended spectrum beta-lactamases
(ESBL) in E. coli is still rare, except in the Clinical Hospital
Center Rebro in Zagreb. The first outbreaks of ESBL-produc-
ing Klebsiella organisms were described in Europe in the mid-
1980s (12), and by 1999 >30% of  Klebsiella isolates from
three of five Zagreb hospitals were resistant to third-generation
cephalosporins. It is already common for Croatian isolates of P.
aeruginosa to be resistant to aminoglycosides, but of new con-
cern is the finding that resistance to imipenem reaches 20% in
some centers. While shigellas are usually multidrug resistant,
salmonellas generally show good sensitivity to antimicrobial
agents, except to ampicillin. ESBL-producing salmonellas,
described as causing outbreaks both in the community and hos-
pitals (6,13,14), were identified in Croatia for the first time in
2000 (unpub. data). 
Anti-TB drug resistance is a particular problem throughout
the world, with multidrug-resistant TB in new cases reaching
>2% in one third of all countries (7,15). With 0.6% of multi-
drug resistance in new cases, Croatia has a low incidence of
multidrug-resistant TB. However, difficulties with isolating
patients and fully implementing the directly observed treat-
ment strategy (16) complicate the situation. 
Apart from providing national data, setting up a surveil-
lance program has heightened awareness of the problem of
antimicrobial resistance throughout Croatia. Both local and
national data are published in the committee’s annual report
and distributed to the participating institutions. Such data are
also discussed at a series of local meetings with clinicians and
used as the basis for local antibiotic policies. The results of this
nationwide surveillance serve as an early warning system for
the emergence of antimicrobial resistance and indicate where
more focused studies are needed. 
The first year’s experience showed that educational and
external quality control programs were needed to supplement
the surveillance program. Training courses organized by the
committee improved the standardization of the laboratory pro-
cedures throughout the country and had great impact on detec-
tion of resistance mechanisms and infection control. By taking
part in the surveillance network, microbiologists were stimu-
lated to discuss antimicrobial resistance and treatment with
ward staff, pharmacists, and managers; sensitivity testing
methods were reviewed; and technical staff were taught to flag
the isolation of resistant bacteria. This process is ongoing.
Laboratory methods need to be kept under continual
review, and introducing a national quality control scheme was
very helpful. An ongoing surveillance program would be
greatly facilitated by the use of microcomputers connected by
e-mail for constructing and updating electronic databases. The
committee also intends to initiate collaboration with the Croat-
ian Ministry of Health to ensure that official policies favor
appropriate use of antimicrobial therapy.
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International Conference on
Emerging Infectious Diseases, 2002
The National Center for Infectious Diseases,
Centers for Disease Control and Prevention, has
scheduled the Third International Conference on
Emerging Infectious Diseases for March 24-27, 2002,
at the Hyatt Regency Hotel, Atlanta, Georgia, USA.
More than 2,500 participants are expected, represent-
ing many nations and disciplines. They will discuss
the latest information on many aspects of new and
reemerging pathogens, such as West Nile virus and
issues concerning bioterrorism.
Conference information is available
at http://www.cdc.gov/iceid
 The Call for Abstracts is available
at http://www.asmusa.org/mtgscr/iceido2.htm
Contact person is Charles Schable, cas1@cdc.gov
Adventure Health Conference 
Navy Pier 
Conference Center
Chicago, Illinois
February 21-24, 2002
Health Issues in Adventure Travel is the focus of a
new education day during the 12th Annual Interna-
tional Adventure Travel Show (IATOS). This seminar
is cosponsored by the Centers for Disease Control and
Prevention, the Wilderness Medical Society, Travel
Health Resource, and the International Society of
Travel Medicine. Session topics include The
Increased Vulnerability of the Adventure Traveler,
Unusual and Exotic Diseases of Adventure Travel,
Minimizing the Risk of a Medical Crisis During Inter-
national Travel, and Travel Wellness: How To Stay Fit
and Health on the Road. In addition, the Division of
Global Migration and Quarantine, National Center for
Infectious Diseases, will present information from
Geosentinel, a global surveillance network of the
International Society of Travel Medicine and CDC,
which monitors infectious diseases among mobile
populations such as international travelers, immi-
grants and refugees.
For more information, contact Jennifer Gordon at
jgordon@msemgmt.com or visit the conference web-
site at www.IATOS.com .